2-formamidomethylisoquinoline | 58021-71-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-formamidomethylisoquinoline
• 英文别名: N-(1-Isochinolylmethyl)formamid；1-Formylaminomethyl-isochinolin；N-isoquinolin-1-ylmethyl-formamide；N-(isoquinolin-1-ylmethyl)formamide
• CAS: 58021-71-9
• 化学式: C₁₁H₁₀N₂O
• 分子量: 186.213
• InChiKey: IOERESUEGAQWSU-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  450.7±28.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-formamidomethylisoquinoline 在 TEA 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.07h， 以86%的产率得到imidazo<5,1-a>isoquinoline
  参考文献：
  名称：

  Langry, Kevin C., Organic Preparations and Procedures International, 1994, vol. 26, # 4, p. 429 - 438

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(1-异喹啉基)甲胺二盐酸盐 以45%的产率得到
  参考文献：
  名称：

  REIMLINGER H.; VANDEWALLE J. J. M.; LINGIER W. R. F.; RUITER E. DE, CHEM. BER. , 1975, 108, NO 12, 3771-3779

  摘要：

  DOI：

文献信息

• Novel isoindole derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US20040053923A1

  公开（公告）日：2004-03-18

  This invention relates to compounds represented by the general formula [I] 1 wherein, R represents an azido group, etc., R 1 and R 2 are the same or different and represent hydrogen atoms, etc., R 3 and R 4 are the same or different and represent hydrogen atoms, etc., X 1 represents an oxygen atom, etc., X 2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及由一般式[I]1表示的化合物，其中，R代表叠氮基等，R1和R2相同或不同，代表氢原子等，R3和R4相同或不同，代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表紧缩芳基基团等，或其药学上可接受的盐，其制备方法以及作为治疗糖尿病的药物、预防糖尿病慢性并发症的预防剂或抗肥胖药物的有效成分，包含该化合物或其药学上可接受的盐。
• NPY Y5 ANTAGONIST
  申请人：KAWANISHI Yasuyuki

  公开号：US20100292500A1

  公开（公告）日：2010-11-18

  The present invention provides a pharmaceutical composition for use as art NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R 1 is lower alkyl, cycloalkyl or the like, R 2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR 7 , CSNR 7 , NR 7 CO, NR 7 CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R 7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.

  本发明提供了一种药物组合物，用作NPY Y5受体拮抗剂，包括化合物或式（I）：其中R1为低碳基、环烷基或类似物，R2为氢、低碳基或类似物，n为1或2，X为低碳基、低烯基、芳基、环烷基或类似物，Y为CONR7、CSNR7、NR7CO、NR7CS或类似物，Z为低碳基、可选取代的碳环基、可选取代的杂环基或类似物，R7为氢或低碳基，前药、药学上可接受的盐或溶剂。
• NOVEL ISOINDOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1207161A1

  公开（公告）日：2002-05-22

  This invention relates to compounds represented by the general formula [I] wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及通式[I]所代表的化合物 其中，R代表叠氮基等，R1和R2相同或不同且代表氢原子等，R3和R4相同或不同且代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表缩合芳基等、或其药学上可接受的盐、其制备工艺，以及含有该化合物或其药学上可接受的盐作为有效成分的治疗糖尿病的药物、治疗糖尿病慢性并发症的预防药物或防治肥胖症的药物。
• Formation of imidazopyridines by the phase transfer catalyzed reaction of .alpha.-(aminomethyl)pyridines and CHCl3 with alkaline hydroxide
  作者：Kevin C. Langry

  DOI：10.1021/jo00007a028

  日期：1991.3

  The reaction of chloroform with 2-(aminomethyl)pyridine (1) under basic phase-transfer catalysis affords the highly fluorescent imidazo[1,5-alpha]pyridine (2) in 25% isolated yield. Despite the formation of considerable tarry residue, GC-MS indicates that the volatile fraction of the reaction is simple and consists of 2 and two minor residue, GC-MS indicates that the volatile fraction of the reaction is simple and consists of 2 and two minor components identified as N-(2-pyridylmethyl)formamide (6) and (2-pyridylmethyl)isonitrile (7). The basic phase transfer catalyzed reaction of chloroform with a series of alpha-(aminomethyl)azanaphthalenes was found to be general and yield the corresponding annulated imidazo derivaties in comparable yields. Despite product yields in the 25% range, GC of the reaction mixtures indicates that the volatile fractions generally consist of residual starting aminomethyl compound, the imidazo product, and a minor amount of the (alpha-azanaphthylmethyl)formamide. However, 3-(aminomethyl)isoquinoline (18) failed to provide any of the expected imidazo[1,5-b]isoquinoline (19). The failure to detect 19 was investigated.
• LANGRY, KEVIN C., J. ORG. CHEM. , 56,(1991) N, C. 2400-2404
  作者：LANGRY, KEVIN C.

  DOI：——

  日期：——